HealthQuill Amgen Inc
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial and the California-based company has started talks with regulators for its approval.
Drugs Health Pharma

Amgen’s trial drug to fight autoimmune disorder improves patient outcomes

Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.

Read More
Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two drugs that treat rare inflammatory diseases.
Drugs Health Pharma

Amgen completes $27.8b acquisition of Horizon Therapeutics

Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two.

Read More